Antimicrobial Susceptibility Testing Market Report 2026

The antimicrobial susceptibility testing market size has grown strongly in recent years. It will grow from $4.65 billion in 2025 to $4.93 billion in 2026 at a compound annual growth rate (CAGR) of 6%. The growth in the historic period can be attributed to rising incidence of infectious diseases, growing awareness of antimicrobial resistance, expansion of clinical microbiology laboratories, increased hospital diagnostic testing volumes, availability of standardized ast protocols.

The antimicrobial susceptibility testing market size is expected to see strong growth in the next few years. It will grow to $6.01 billion in 2030 at a compound annual growth rate (CAGR) of 5.1%. The growth in the forecast period can be attributed to increasing investments in rapid diagnostic technologies, rising adoption of ai-assisted laboratory analysis, expansion of surveillance programs for antimicrobial resistance, growing demand for point-of-care ast solutions, increasing focus on precision antimicrobial therapy. Major trends in the forecast period include increasing adoption of automated ast systems, rising demand for rapid diagnostic testing, growing integration of molecular and phenotypic methods, expansion of laboratory automation solutions, enhanced focus on antimicrobial resistance monitoring.

The increasing prevalence of infectious diseases worldwide has contributed to the growth of the antimicrobial susceptibility testing market. Infectious diseases are caused by microorganisms such as bacteria, viruses, fungi, and parasites. Examples of bacterial infections include bacterial pneumonia and tuberculosis, while viral infections include smallpox, AIDS, and others. For example, in March 2024, according to the Centers for Disease Control and Prevention, a US-based national public health agency, in 2023, among 9,573 TB cases in individuals with known birth origin, 7,259 (76%) occurred in non-U.S.-born persons, representing an 18% increase compared with the 6,177 cases reported in 2022. Consequently, the rising prevalence of infectious diseases is fueling the growth of the antimicrobial susceptibility testing market.

Major companies operating in the antimicrobial susceptibility testing market are focusing on developing innovative products, such as the First POC Testing System. The First POC Testing System identifies the presence or absence of bacteria and evaluates the effectiveness of antimicrobials using urine samples from patients suspected of urinary tract infections (UTIs). This represents a notable advancement in AST technologies and aids in accelerating the initiation of targeted antimicrobial therapy for infected patients. For example, in June 2023, Sysmex Corporation, a Japan-based company that produces reagents and equipment for clinical tests, including hematologic (blood) and immune tests, introduced a testing system for rapid antimicrobial susceptibility detection. Leveraging a unique and proprietary microfluidic technology, the system provides antimicrobial susceptibility testing (AST) results in as little as 30 minutes from the start of measurement, considerably faster than the several days required by conventional AST methods.

In May 2024, Pfizer, a US-based biopharmaceutical company, formed a partnership with bioMérieux to enhance antimicrobial stewardship through advanced diagnostics. The collaboration aims to combine bioMérieux’s advanced diagnostic technologies with Pfizer’s healthcare initiatives to improve infection surveillance, support antimicrobial susceptibility testing, and encourage appropriate and rational antibiotic use across Malawi’s public central hospitals. bioMérieux, a France-based company, provides a broad range of microbial detection and antimicrobial susceptibility testing solutions that facilitate evidence-based treatment decisions.

Major companies operating in the antimicrobial susceptibility testing market are BioMérieux SA, Becton Dickinson and Company, Thermo Fisher Scientific Inc., Danaher Corporation, Bio-Rad Laboratories Inc., Accelerate Diagnostics Inc., Alifax Holding S.p.A., Synbiosis Ltd., Mast Group Ltd., ELITechGroup, Genefluidics Inc., QuantaMatrix Inc., Bruker Corporation, Eurofins Scientific SE, Liofilchem s.r.l., Hardy Diagnostics, Bioanalyse GmbH, Lab M Limited, Microbiologics Inc., Quidel Corporation, R-Biopharm AG, SSI Diagnostica A/S.

North America was the largest region in the antimicrobial susceptibility testing market in 2025. Asia-Pacific is expected to be the fastest growing region in the forecast period. The regions covered in the antimicrobial susceptibility testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the antimicrobial susceptibility testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the antimicrobial susceptibility testing market by increasing costs of imported laboratory instruments, automated analyzers, reagents, consumables, and diagnostic software systems. Hospitals and diagnostic laboratories in North America and Europe are most affected due to reliance on imported testing equipment, while Asia-Pacific faces higher costs for manufacturing and exporting diagnostic instruments. These tariffs are raising operational expenses and slowing laboratory upgrade cycles. However, they are also encouraging local production of diagnostic kits, regional instrument assembly, and domestic innovation in laboratory testing technologies.

The antimicrobial susceptibility testing market research report is one of a series of new reports that provides antimicrobial susceptibility testing market statistics, including antimicrobial susceptibility testing industry global market size, regional shares, competitors with a antimicrobial susceptibility testing market share, detailed antimicrobial susceptibility testing market segments, market trends and opportunities, and any further data you may need to thrive in the antimicrobial susceptibility testing industry. This antimicrobial susceptibility testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Antimicrobial susceptibility testing (AST) is a laboratory procedure performed by clinical laboratory professionals to determine which antimicrobial agent is most effective for individual patients. The antimicrobial susceptibility testing market includes sales of antimicrobial susceptibility testing by entities (organizations, sole proprietors, and partnerships) that are involved in laboratory services offering antimicrobial susceptibility testing.

The main types of antimicrobial susceptibility testing (AST) procedures include antibacterial testing, antifungal testing, antiparasitic testing, and others. Antifungal susceptibility testing assesses the ability of a specific organism to grow in vitro in the presence of a particular drug. AST products used in these tests include manual antimicrobial susceptibility testing products, automated laboratory instruments, and other consumables. These products are applied in diagnostics, drug discovery and development, and epidemiology. Antimicrobial susceptibility testing is utilized by hospitals and diagnostic centers, pharmaceutical and biotechnology companies, research and academic institutes, and clinical research organizations (CROs).

The antimicrobial susceptibility testing (AST) market includes revenues earned by dilution susceptibility tests and disc diffusion susceptibility tests. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.